All Updates

All Updates

icon
Filter
FDA approval
Biotricity receives FDA approval for its cardiac monitoring device
Telehealth
Jan 24, 2022
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Yesterday
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Yesterday
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Yesterday
Partnerships
Climeworks partners with Terraset to enable philanthropic support for carbon removal
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Funding
8 Rivers secures investment from JX Nippon to commercialize DAC technology
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Sep 17, 2024
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Sep 17, 2024
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Sep 17, 2024
Jan 24, 2022

Biotricity receives FDA approval for its cardiac monitoring device

FDA approval

  • Biotricity, a remote patient monitoring company, has received the US Food and Drug Administration (FDA)-clearance for its cardiac monitoring device, Biotres. The company claims Biotres is the first device to provide continuous 3 channel recording of electrocardiogram (ECG) data.

  • The wearable holder patch records real-time ECG data for early detection of cardiac arrhythmias focusing on lower-risk patients. The technology allows cardiologists to access collected cardiac data for warning signs and integrates with existing health systems, facilitating cardiac prevention and monitoring. It can be worn continuously for 48 hours after a single charge and will be available to the users from April 2022.

  • The device is expected to expand Biotricity’s product portfolio and market reach from USD 1 billion to USD 5.7 billion. The FDA approval comes after the company raised non-dilutive financing of USD 12 million in December 2021.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.